Chemotherapy with cisplatin and vincristine for optic pathway/ hypothalamic astrocytoma in young children

Japanese Journal of Clinical Oncology

Volumn 39, Issue 5, 2009, Pages 277-283

  Sawamura, Yutaka ^a   Kamoshima, Yuuta ^a   Kato, Tsutomu ^a   Tajima, Toshihiro ^a   Tsubaki, Junko ^a  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Cisplatin; Hypothalamus; Pilocytic astrocytoma; Vincristine

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; HEARING LOSS; HEARING TEST; HISTOPATHOLOGY; HUMAN; HYDROCEPHALUS; INFANT; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPTIC PATHWAY HYPOTHALAMIC ASTROCYTOMA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PILOCYTIC ASTROCYTOMA; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOTHALAMIC NEOPLASMS; INFANT; MALE; TREATMENT OUTCOME; VINCRISTINE; VISUAL PATHWAYS;

EID: 65549167245     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp012     Document Type: Article

References (43)

1. Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: Relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001;131:442-5.
2. Brown MT, Friedman HS, Oakes WJ, Boyko OB, Hockenberger B, Schold SC, Jr. Chemotherapy for pilocytic astrocytomas. Cancer 1993;71:3165-72.
3. Cappelli C, Grill J, Raquin M, Pierre-Kahn A, Lellouch-Tubiana A, Terrier-Lacombe M-J, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child 1998;79:334-8.
4. Fouladi M, Wallace D, Langston JW, Mulhern R, Rose SR, Gajjar A, et al. Survival and functional outcome of children with hypothalamic chiasmatic tumors. Cancer 2003;97:1084-92.
5. Laithier V, Grill J, Le Deley MC, Ruchoux M-M, Couanet D, Doz F, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy - results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 2003;21:4572-8.
6. Opocher E, Kremer LC, Da Dalt L, van de Wetering MD, Viscardi E, Caron HN, et al. Prognostic factors for progression of childhood optic pathway glioma: A systematic review. Eur J Cancer 2006;42:1807-16.
7. Steinbok P, Hentschel S, Almqvist P, Cochrane DD, Poskitt K. Management of optic chiasmatic/hypothalamic astrocytomas in children. Can J Neurol Sci 2002;29:132-8.
8. Sutton LN, Molloy PT, Sernyak H, Goldwein J, Phillips PL, Rorke LB, et al. Long-term outcome of hypothalamic chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg 1995;83:583-9.
9. Tow SL, Chandela S, Miller NR. Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 2003;28: 262-70.
10. Chan MY, Foong AP, Heisey DM, Harkness W, Hayward R, Michalski A. Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: A multivariate analysis. Pediatr Neurosurg 1998;29: 23-8.
11. Komotar RJ, Burger PC, Carson BS, Brem H, Olivi A, Goldthwaite PT, et al. Pilocytic and pilomyxoid hypothalamic chiasmatic astrocytomas. Neurosurgery 2004;54:72-9.
12. Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, et al. High response rate to cisplatin etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002;20:4209-16.
13. Silva MM, Goldman S, Keating G, Marymont MA, Kalapurakal J, Tomita T. Optic pathway hypothalamic gliomas in children under three years of age: the role of chemotherapy. Pediatr Neurosurg 2000;33;:151-8.
14. Tihan T, Fisher PG, Kepner JL, Godfraind C, McComb RD, Goldthwaite PT, et al. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol 1999;58:1061-8.
15. Hoffman HJ, Humphreys RP, Drake JM, Rutka JT, Becker LE, Jenkin D, et al. Optic pathway/hypothalamic gliomas: A dilemma in management. Pediat Neurosurg 1993;19:186-95.
16. Sawamura Y, Kamada K, Kamoshima Y, Yamaguchi S, Tajima T, Tsubaki J, et al. Role of surgery for optic pathway/hypothalamic astrocytomas in children. Neuro Oncol 2008;10:725-33.
17. Wisoff JH, Abbott R, Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 1990;73:661-7.
18. Erkal HS, Serin M, Cakmak A. Management of optic pathway and chiasmatic-hypothalamic gliomas in children with radiation therapy. Radiother Oncol 1997;45:11-5.
19. Grill J, Laithier V, Rodriguez D, Raquin MA, Pierre-Kahn A, Kalifa C. When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 2000;159:692-6.
20. Fisher BJ, Bauman GS, Leighton CE, Stitt L, Cairncross JG, Macdonald DR. Low-grade gliomas in children: Tumor volume response to radiation. J Neurosurg 1998;88:969-74.
21. Janss AJ, Grundy R, Cnaan A, Savino PJ, Packer RJ, Zackai EH, et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 1995;75:1051-9.
22. Lacaze E, Kieffer V, Streri A, Lorenzi C, Gentaz Ez, Habrand J-L, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer 2003;89:2038-44.
23. Marcus KJ, Goumnerova L, Billett AL, Lavally B, Scott RM, Bishop K, et al. Stereotactic radiotherapy for localized low-grade gliomas in children: Final results of a prospective trial. Int J Radiat Oncol Biol Phys 2005;61:374-9.
24. Tao ML, Barnes PD, Billett AL, Leong T, Shrieve D, Scott R, et al. Childhood optic chiasm gliomas: Radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys 1997;39:579-87.
25. Packer RJ, Savino PJ, Bilaniuk LT, Zimmerman RA, Schatz NJ, Rosenstock JG, et al. Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation. Childs Brain 1983;10:393-403.
26. Aquino VM, Fort DW, Kamen BA. Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: A phase II study. J Neurooncol 1999;41:255-9.
27. Gnekow AK, Kortmann RD, Pietsch T, Emser A. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristine chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy - report from the multicenter treatment study for children and adolescents with a low grade glioma - HIT-LGG 1996 - of the Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004;216:331-42.
28. Gururangan S, Cavazos CM, Ashley D, Herndon JE, Bruggers CS, Moghrabi A, et al. Phase II study of Carboplatin in children with progressive low-grade gliomas. J Clin-Oncol 2002;20:2951-8.
29. Kato T, Sawamura Y, Tada M, Ikeda J, Ishii N, Abe H. Cisplatin/ vincristine chemotherapy for hypothalamic/visual pathway astrocytomas in young children. J Neuro-Oncol 1998;37:263-70.
30. Mahoney DH, Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study. Neuro-Oncol 2000;2:213-20.
31. Mitchell AE, Elder JE, Mackey DA, Waters KD, Ashley DM. Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas. J Pediatr Hematol Oncol 2001;23:572-7.
32. Moghrabi A, Friedman HS, Burger PC, Tien R, Oakes WJ. Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. J Neurosurg 1993;79:223-7.
33. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86: 747-54.
34. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850-6.
35. Packer RJ, Sutton LN, Bilaniuk LT, Radcliffe J, Rosenstock JG, Siegel KR, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: An update. Ann Neurol 1988;23:79-85.
36. Prados MD, Edwards MSB, Rabbitt J, Lamborn K, Davis RL, Levin VA. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997;32:235-41.
37. Gnekow AC. Recommendations of th Brain Tumor Subcommittee for the reporting of trials: SIOP Brain Tumor Subcommittee-International Society of Pediatric Oncology. Med Pediatr Oncol 1995;24:104-8.
38. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22.
39. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 1998;9:13-21.
40. Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro-Oncol 2007;9:161-8.
41. Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 2003;25:372-8.
42. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646-51.
43. Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Ute Bartels U, Tabori U, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005;103:2636-42.